Trial Search Results

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Procedure: Assessment of Therapy Complications
  • Other: Questionnaire Administration

Eligibility


Inclusion Criteria:

   - The patient must be enrolled on a frontline COG therapeutic trial for treatment of a
   primary malignancy;or the patient must have been enrolled on a COG (or Legacy Group)
   therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1

      - Hodgkin lymphoma

         - CCG 5942

         - POG 9425

         - POG 9426

         - AHOD0031

         - AHOD1331

         - S1826 (COG patients only)

      - Brain tumor

         - A9961

      - Acute lymphoblastic leukemia

         - POG 9404

      - Osteosarcoma

         - POG 9754

      - Stem cell transplantation

         - ASCT0631D

      - Rhabdomyosarcoma

         - IRS-III

         - IRS-IV

      - Late Effects Protocols with Patients Eligible for Enrollment on ALTE05N1

         - ALTE15N1

         - ALTE16C1

      - Enrollment on ALTE05N1 must occur within 24 calendar months of the date the
      patient was enrolled on a frontline COG therapeutic trial; or patients previously
      enrolled on a COG (or Legacy Group) trial targeted for long term follow-up by
      ALTE05N1 may enroll on ALTE05N1 at any time

   - The patient must reside in the U.S. on the date of enrollment to ALTE05N1

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jenny Joaquin
650-723-0618
Recruiting